U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C8H19NO
Molecular Weight 145.2426
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HEPTAMINOL

SMILES

CC(N)CCCC(C)(C)O

InChI

InChIKey=LREQLEBVOXIEOM-UHFFFAOYSA-N
InChI=1S/C8H19NO/c1-7(9)5-4-6-8(2,3)10/h7,10H,4-6,9H2,1-3H3

HIDE SMILES / InChI
Molecular Formula C8H19NO
Molecular Weight 145.2426
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Heptaminol is an amino alcohol that has been used as a myocardial stimulant and vasodilator and to relieve bronchospasm. Its most common therapeutic use is in orthostatic hypotension. The mechanism of heptaminol's therapeutic actions is not well understood although it has been suggested to affect catecholamine release or calcium metabolism.

CNS Activity

CNS Active
3913
Curator's Comment: Heptaminol (Corasore®) is a cardiac stimulant having a positive inotropic action. It increases coronary blood flow with a slight peripheral vasoconstrictor properties and mild C.N.S. stimulant effect.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 15.3 µM [IC50]
Inhibitor
8297
 60.0 µM [Ki]
Inhibitor
8297
 650.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Corasore

Approved Use

Is for the treatment of hypotension, fainting tendency and slight to moderately severe circulatory collapse; Asthenia, nervous and physical fatigue in general and sporting medicine; Adjuvant treatment of mild and moderate cases of heart failure particularly incipient pulmonary edema; Heart failure associated with toxic, infectious, degenerative orarteriosclerotic myocardial disease; Neonatal asphyxia.
PubMed

PubMed

TitleDatePubMed
Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatic hypotension in parkinsonians.
1990
Heptaminol interferes in the AxSYM FPIA amphetamine/methamphetamine II assay.
2001 Aug
Clinical study of the Ginko biloba--Troxerutin-Heptaminol Hce in the treatment of acute hemorrhoidal attacks.
2004 Feb
Metabolism of isometheptene in human urine and analysis by gas chromatography-mass spectrometry in doping control.
2005 Dec 5
Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France.
2005 Jul
Heat-related morbidity in patients with orthostatic hypotension and primary autonomic failure.
2005 Sep
Solid-phase column chromatographic and gas chromatographic-mass spectrometric determination of heptaminol in human urine and related pharmacokinetic profiles.
2006 Jul-Aug
Hair lightening in an hemodialysis patient treated by heptaminol (heptamyl).
2009 Apr 15
Patents

Patents

EP0291436B1
2
US3993639
2
US4315924
2

Sample Use Guides

In Vivo Use Guide
Infants & children under 12 years: 4-16 drops (25 -100 mg) depending on age, 2 – 4 times daily, up to 6 times daily if necessary, or as directed by the physician. Adults & children over 12 years: One tablet or 25 drops, (150 mg) 2-4 times daily, up to 6 times daily.
Route of Administration: Oral
In Vitro Use Guide
1. The effects of heptaminol on calcium current amplitude and characteristics were studied in single ventricular myocytes of guinea-pig by use of the whole cell configuration of the patch clamp technique. 2. A concentration-dependent decrease in ICa amplitude was observed. At heptaminol concentration as low as 10(-6) M, this effect was observed in only two cells (n = 6). At 10(-5) M the reduction of ICa was of 30 +/- 15% (n = 11). Both at -40 mV and -80 mV HP, heptaminol (10(-5) M) significantly increased the steady state inactivation of ICa.
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:12:57 UTC 2023
Edited
by admin
on Fri Dec 15 19:12:57 UTC 2023
Record UNII
3DQS188SY5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HEPTAMINOL
INN   MI   WHO-DD  
INN  
Official Name English
heptaminol [INN]
Common Name English
6-AMINO-2-METHYL-2-HEPTANOL
Systematic Name English
2-AMINO-6-HYDROXY-6-METHYLHEPTANE
Systematic Name English
6-HYDROXY-6-METHYL-2-AMINOHEPTANE
Systematic Name English
(5-HYDROXY-1,5-DIMETHYLHEXYL)AMINE
Systematic Name English
GINKOR
Brand Name English
6-METHYL-2-AMINO-6-HEPTANOL
Systematic Name English
2-METHYL-6-AMINO-2-HEPTANOL
Systematic Name English
6-HYDROXY-6-METHYL-2-HEPTAMINE
Common Name English
Heptaminol [WHO-DD]
Common Name English
6-HYDROXY-6-METHYL-2-HEPTYLAMINE
Systematic Name English
HEPTAMINOL [MI]
Common Name English
2-HEPTANOL, 6-AMINO-2-METHYL-
Systematic Name English
CORASORE
Brand Name English
Classification Tree Code System Code
WHO-ATC C01DX08
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
WHO-VATC QC01DX08
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
Code System Code Type Description
DAILYMED
3DQS188SY5
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
MERCK INDEX
m5962
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY Merck Index
DRUG BANK
DB13574
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
EPA CompTox
DTXSID4048484
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
PUBCHEM
3590
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
MESH
D006535
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
WIKIPEDIA
HEPTAMINOL
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
NCI_THESAURUS
C166673
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
SMS_ID
100000083949
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
ECHA (EC/EINECS)
206-758-0
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
ChEMBL
CHEMBL2111076
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
RXCUI
5254
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY RxNorm
DRUG CENTRAL
1361
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
FDA UNII
3DQS188SY5
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
EVMPD
SUB08016MIG
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
CAS
372-66-7
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
INN
2030
Created by admin on Fri Dec 15 19:12:57 UTC 2023 , Edited by admin on Fri Dec 15 19:12:57 UTC 2023
PRIMARY
Related Record Type Details
Structure of HEPTAMINOL HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of ACEFYLLINE HEPTAMINOL
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of 6-METHYLHEPT-5-EN-2-AMINE, (±)-
IMPURITY -> PARENT
Related Record Type Details
Structure of HEPTAMINOL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966